Hyperfine, Inc. Appoints New Director and CMO
Ticker: HYPR · Form: 8-K · Filed: May 23, 2025 · CIK: 1833769
| Field | Detail |
|---|---|
| Company | Hyperfine, Inc. (HYPR) |
| Form Type | 8-K |
| Filed Date | May 23, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, board-of-directors, executive-appointment
TL;DR
Hyperfine's board is changing: Evelyn out, Shavelle in as director & CMO.
AI Summary
Hyperfine, Inc. announced on May 21, 2025, the departure of director Dr. Jonathan S. B. T. Evelyn and the election of new director Dr. David M. Shavelle. The company also appointed Dr. Shavelle as Chief Medical Officer and announced a new compensatory arrangement for him.
Why It Matters
Changes in board composition and executive appointments can signal shifts in company strategy or leadership focus.
Risk Assessment
Risk Level: medium — Changes in key leadership and board members can introduce uncertainty regarding future strategy and execution.
Key Players & Entities
- Hyperfine, Inc. (company) — Registrant
- Dr. Jonathan S. B. T. Evelyn (person) — Departing Director
- Dr. David M. Shavelle (person) — Newly Elected Director and Chief Medical Officer
- HealthCor Catalio Acquisition Corp. (company) — Former Company Name
- May 21, 2025 (date) — Date of earliest event reported
FAQ
Who has departed from Hyperfine, Inc.'s board of directors?
Dr. Jonathan S. B. T. Evelyn has departed from Hyperfine, Inc.'s board of directors as of May 21, 2025.
Who has been elected as a new director to Hyperfine, Inc.'s board?
Dr. David M. Shavelle has been elected as a new director to Hyperfine, Inc.'s board.
What other role has Dr. David M. Shavelle taken on at Hyperfine, Inc.?
Dr. David M. Shavelle has also been appointed as the Chief Medical Officer of Hyperfine, Inc.
What is the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported in this 8-K filing is May 21, 2025.
What is the principal executive office address for Hyperfine, Inc.?
The principal executive office address for Hyperfine, Inc. is 351 New Whitfield Street, Guilford, Connecticut 06437.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 23, 2025 by Dr. Jonathan S. B. T. Evelyn regarding Hyperfine, Inc. (HYPR).